Literature DB >> 11577264

Applying scientific criteria to therapeutic interchange: a balanced analysis of low-molecular-weight heparins.

G J Merli1, G J Vanscoy, T L Rihn, J B Groce, W McCormick.   

Abstract

Under pressure to provide cost-effective healthcare, many healthcare systems have adopted Therapeutic Interchange (TI) programs-the interchange of therapeutically equivalent but chemically unique drugs-to reduce the total cost of therapy without compromising patient care. To be appropriate and feasible, a TI program for any class of drugs must meet certain rigorous criteria and undergo medical, financial, tactical, and legal reviews. Moreover, once a TI program is implemented, a process to monitor its success should be established. Application of the TI criteria to low-molecular-weight heparins (LMWHs) reveals that a blanket TI program for LMWHs does not appear advisable at this time.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11577264     DOI： 10.1023/a:1011969005756

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN： 0929-5305            Impact factor:   2.300


  51 in total

1.  Therapeutic interchange of low-molecular-weight heparins.

Authors:  T G Burnakis
Journal:  Am J Health Syst Pharm       Date:  2000-10-01       Impact factor: 2.637

Review 2.  Can we differentiate the low-molecular-weight heparins?

Authors:  A G Turpie
Journal:  Clin Cardiol       Date:  2000-01       Impact factor: 2.882

3.  Will the use of low-molecular-weight heparin (enoxaparin) in patients with acute coronary syndrome save costs in Canada?

Authors:  B J O'Brien; A Willan; G Blackhouse; R Goeree; M Cohen; S Goodman
Journal:  Am Heart J       Date:  2000-03       Impact factor: 4.749

Review 4.  Pharmacokinetics of low molecular weight heparins in animal models.

Authors:  J Fareed; K Fu; L H Yang; D A Hoppensteadt
Journal:  Semin Thromb Hemost       Date:  1999       Impact factor: 4.180

5.  ASHP statement on the formulary system.

Authors: 
Journal:  Am J Hosp Pharm       Date:  1986-11

6.  From the Food and Drug Administration.

Authors:  S L Nightingale
Journal:  JAMA       Date:  1993-10-13       Impact factor: 56.272

7.  Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A cost-effectiveness analysis.

Authors:  M K Gould; A D Dembitzer; G D Sanders; A M Garber
Journal:  Ann Intern Med       Date:  1999-05-18       Impact factor: 25.391

8.  A comparison of low-dose heparin with low-molecular-weight heparin as prophylaxis against venous thromboembolism after major trauma.

Authors:  W H Geerts; R M Jay; K I Code; E Chen; J P Szalai; E A Saibil; P A Hamilton
Journal:  N Engl J Med       Date:  1996-09-05       Impact factor: 91.245

9.  Long-term low-molecular-mass heparin in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. FRagmin and Fast Revascularisation during InStability in Coronary artery disease. Investigators.

Authors: 
Journal:  Lancet       Date:  1999-08-28       Impact factor: 79.321

10.  1999 update: ACC/AHA guidelines for the management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction).

Authors:  T J Ryan; E M Antman; N H Brooks; R M Califf; L D Hillis; L F Hiratzka; E Rapaport; B Riegel; R O Russell; E E Smith; W D Weaver; R J Gibbons; J S Alpert; K A Eagle; T J Gardner; A Garson; G Gregoratos; T J Ryan; S C Smith
Journal:  J Am Coll Cardiol       Date:  1999-09       Impact factor: 24.094
View more
  7 in total

Review 1.  Choice of agents to limit the coagulation cascade in acute coronary syndromes.

Authors:  Richard C Becker
Journal:  Curr Cardiol Rep       Date:  2002-07       Impact factor: 2.931

Review 2.  Biosimilars of low molecular weight heparins: Relevant background information for your drug formulary.

Authors:  Jacobus R B J Brouwers; Jeanine E Roeters van Lennep; Maarten J Beinema
Journal:  Br J Clin Pharmacol       Date:  2019-09-04       Impact factor: 4.335

3.  Systematic literature review of the methodology for developing pharmacotherapeutic interchange guidelines and their implementation in hospitals and ambulatory care settings.

Authors:  Maria Adrover-Rigo; Maria-Dolores Fraga-Fuentes; Francesc Puigventos-Latorre; Iciar Martinez-Lopez
Journal:  Eur J Clin Pharmacol       Date:  2018-10-19       Impact factor: 2.953

4.  Scientific considerations in the review and approval of generic enoxaparin in the United States.

Authors:  Sau Lee; Andre Raw; Lawrence Yu; Robert Lionberger; Naiqi Ya; Daniela Verthelyi; Amy Rosenberg; Steve Kozlowski; Keith Webber; Janet Woodcock
Journal:  Nat Biotechnol       Date:  2013-03       Impact factor: 54.908

5.  Comparative glycomics using a tetraplex stable-isotope coded tag.

Authors:  Michael J Bowman; Joseph Zaia
Journal:  Anal Chem       Date:  2010-04-01       Impact factor: 6.986

6.  Pharmacological and clinical differences between low-molecular-weight heparins: implications for prescribing practice and therapeutic interchange.

Authors:  Geno J Merli; James B Groce
Journal:  P T       Date:  2010-02

Review 7.  Therapeutic Interchange of Parenteral Anticoagulants: Challenges for Pharmacy and Therapeutics Committees.

Authors:  Alpesh Amin
Journal:  Pharmaceuticals (Basel)       Date:  2011-11-07
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.